Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Trastuzumab in early breast cancer
Presse Medicale, Volume 42, No. 7-8, Year 2013
Notification
URL copied to clipboard!
Description
Background: The HER2gene or c-erb B2or neu is amplified in 15-25% of breast cancers. This amplification is associated with an aggressive course of disease. The trastuzumab is a monoclonal antibody targeting the extracellular domain of HER2. This is the first targeted molecule designed to treat breast cancer. In the firstline metastatic disease, trastuzumab in combination with chemotherapy significantly improved survival of patients with HER2-positive disease. In the adjuvant setting, trastuzumab has been evaluated in several randomized trials. Objective: The purpose of this literature review is to evaluate the efficacy and safety of Trastuzumab in the adjuvant treatment of HER2-positive breast cancer. Methods: A search of articles published in English literature, between 1987 (date of establishment of prognostic value of HER2) and November 2012, was conducted on Medline and in the database of the main international congress using the following terms: "breast cancer", "HER2-positive", "adjuvant therapy" and "Trastuzumab". Results: We identified seven randomized phase 3trial evaluating trastuzumab in the adjuvant treatment of HER2-positive. The trastuzumab was administered weekly or every 3. weeks. Its administration with concomitant taxane chemotherapy and with concurrent radiotherapy was preferred. Four randomized trials have clearly confirmed the benefit of trastuzumab, two positive in overall survival (OS) and progression free survival (PFS), and two positive in PFS. The duration of trastuzumab for 1. year was the most effective. The trastuzumab was well tolerated. The most significant toxicity, associated with trastuzumab, was cardiac toxicity. However, it is found in only 5% or less of cases, and it is severe in only 2% or less of cases, and most patients recovered their cardiac function by medical treatment alone. Conclusion: In the contemporary medical literature, several strong arguments confirm the benefit in survival of trastuzumab administered concomitantly with a taxane-based chemotherapy and with concurrent radiotherapy, and for a period of 1. year. Trastuzumab was well tolerated. Only 2% or less of patients experienced a serious cardiac toxicity, but it was reversible in most of the time. © 2013 Elsevier Masson SAS.
Authors & Co-Authors
Ismaili, Nabil
Morocco, Marakech
Chu Mohammed-vi
Elmajjaoui, Sanaa
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Tahri, Ali
Morocco, Marakech
Clinique Spécialisée Menara
Benjaafar, Noureddine
Morocco, Agdal Rabat
Ibn Sina Hospital, Agdal Rabat
Errihani, Hassan H.
Morocco, Marakech
Chu Mohammed-vi
Belbaraka, Rhizlane
Morocco, Marakech
Chu Mohammed-vi
Statistics
Citations: 6
Authors: 6
Affiliations: 3
Identifiers
Doi:
10.1016/j.lpm.2013.01.054
ISSN:
07554982
Research Areas
Cancer
Noncommunicable Diseases
Study Approach
Systematic review